
Solventum Corporation (SOLV) Stock Forecast & Price Target
Solventum Corporation (SOLV) Analyst Ratings
Bulls say
Solventum is expected to continue its strong performance with organic growth in all segments and plans for offensive M&A, share repurchases, and debt repayment. The company is facing risks such as competition and institutional selling from its majority owner, but is expected to see positive changes in reimbursement and valuation. Overall, SOLV has a positive outlook with a Buy rating and projected annual top line growth of 4%.
Bears say
Solventum is a healthcare company with a diversified portfolio of products and solutions, but its most profitable segment, MedSurg, faces potential challenges such as decreasing healthcare spending and increased competition. Additionally, the company has a high level of debt and its margins have not yet reached the targets set at the company's Analyst Day in FY25, raising concerns about the effectiveness of its cost-cutting measures. Furthermore, post-spin separation activities from parent company 3M and potential stock dilution from secondary offerings could also impact Solventum's stock performance in the near-term.
This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.
Solventum Corporation (SOLV) Analyst Forecast & Price Prediction
Start investing in Solventum Corporation (SOLV)
Order type
Buy in
Order amount
Est. shares
0 shares